SANTA CLARA, Calif., June 12, 2018 /PRNewswire/ -- Frost & Sullivan, the growth partnership company, announced today
For more information and to register for the webinar, please visit: http://frost.ly/2iz
"Digital therapeutics represents the synthesis of traditional bits and bytes and small and large molecules that will transform the patient experience," explains Camlek. "Patients will benefit from new solutions aimed at behavior modification based on a combination of training, social networking and 24x7 patient guidance that should improve the potential that they will adhere to prescribed therapies or eliminate the need to rely solely on medication to manage chronic conditions."
In addition, digital therapeutics presents a significant opportunity for traditional pharmaceutical therapeutics and information technology (IT) capabilities to converge over time to influence a new approach to increase positive patient outcomes while reducing the overall cost of healthcare.
"Digital therapeutics also appears as an advanced level of solutions from mHealth companies that will combine applications, patient education, professional intervention, and peer support that will increase patient engagement and medication adherence by augmenting or replacing traditional drug therapeutics," notes Ruppar.
This timely webinar coincides with the U.S. Food and Drug Administration (FDA) PreCertification Program, described by the FDA as a "first-of-its-kind pilot program that will help revolutionize digital health regulation in the U.S." The FDA wants to learn more about the methods utilized by software developers and digital health developers. This is an important milestone in the evolution of digital therapeutics observes Camlek.
The informative webinar will cover key insights:
The event will also be recorded and available for on-demand viewing at http://frost.ly/1ti.
About Frost & SullivanFrost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion
For more information, visit ww2.frost.com or call +1 (877) 463-7678.
Press Contact:Mariana FernandezFrost & Sullivan +1 (210) firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/explore-how-digital-therapeutics-boost-medical-workflow-and-patient-communications-300665007.html
SOURCE Frost & Sullivan
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All